Carbonic Anhydrase Inhibitors: Identifying Therapeutic Cancer Agents Through Virtual Screening
Progress in Drug Research, ISSN: 2297-4555, Vol: 75, Page: 237-252
2021
- 1Citations
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations1
- Citation Indexes1
Book Chapter Description
Computer-aided drug design includes an ensemble of different in silico strategies that represent valuable tools for facilitating the discovery and optimization of novel hit compounds endowed with biological activity toward the desired target proteins. Due to the various pathological implications of carbonic anhydrases (CAs), especially in the development and progression of cancer, molecular modeling techniques have been widely applied for the identification of new CA inhibitors. In this chapter, after providing the reader with a brief introduction to computational methods in drug design, we summarize the results of the main virtual screening (VS) studies that led to the discovery of novel ligands of different CA isoforms, describing the various receptor-based and ligand-based approaches employed. Moreover, we report the results of retrospective analyses in which CAs and their known ligands have been used to validate the performance of various VS methods in hit identification. The present chapter should provide the reader with a panoramic view of the most used and reliable in silico techniques to be applied in the search for novel CA inhibitors.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85118472257&origin=inward; http://dx.doi.org/10.1007/978-3-030-79511-5_11; https://link.springer.com/10.1007/978-3-030-79511-5_11; https://link.springer.com/content/pdf/10.1007/978-3-030-79511-5_11; https://dx.doi.org/10.1007/978-3-030-79511-5_11; https://link.springer.com/chapter/10.1007/978-3-030-79511-5_11
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know